OIG Allows Drug Maker to Pay for Lab Test That Determines Whether Patients Need Its Drug
- July 11, 2025
A drug manufacturer’s proposal to sponsor a companion laboratory test for eligible patients to determine if the requestor’s drug is an appropriate treatment could generate prohibited remuneration under the Anti-Kickback Statute (AKS), but the Department of Health and Human Services Office of Inspector General (OIG) said in an advisory opinion posted July 2 that it will not impose administrative sanctions on the arrangement.
ARTICLE TAGS
You must be logged in to access this content.